Cardiotoxicity: Trastuzumab and cancer survivors

International Journal of Cardiology

Volumn 177, Issue 2, 2014, Pages 554-556

  Patanè, Salvatore ^a  

^a Cardiologia Ospedale San Vincenzo   (Italy)

Author keywords

Cancer chemotherapy; Cardio oncology; Cardiotoxicity; Her2 Trastuzumab

Indexed keywords

EID: 85027921558     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.08.117     Document Type: Article

References (89)

1. E. Conti, A. Romiti, and M.B. Musumeci Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors Int J Cardiol 167 6 Sep 10 2013 2421 2429
2. S. Rateesh, S.A. Luis, C.R. Luis, B. Hughes, and M. Nicolae Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge? Int J Cardiol 172 2 Mar 15 2014 e331 e333
3. S. Kurisu, T. Iwasaki, K. Ishibashi, N. Mitsuba, Y. Dohi, and Y. Kihara Comparison of treatment and outcome of acute myocardial infarction between cancer patients and non-cancer patients Int J Cardiol 167 5 Sep 1 2013 2335 2337
4. J.M. Scott, L.W. Jones, and W.E. Hornsby Cancer therapy-induced autonomic dysfunction in early breast cancer: implications for aerobic exercise training Int J Cardiol 171 2 Feb 1 2014 e50 e51
5. S. Claridge, A. Chakrabarti, K. Greaves, and C.J. Boos Successful use of trastuzumab following cardiac resynchronisation therapy Int J Cardiol 166 2 Jun 20 2013 e33 e34
6. M. Lotrionte, G. Palazzoni, and A. Abbate Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue doppler imaging Evaluation) randomized pilot study Int J Cardiol 167 3 Aug 10 2013 1055 1057
7. M.G. Kaya, M. Ozkan, and O. Gunebakmaz Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study Int J Cardiol 167 5 Sep 1 2013 2306 2310
8. Y. Ozkanlar, M.S. Aktas, and M. Turkeli Effects of ramipril and darbepoetin on electromechanical activity of the heart in doxorubicin-induced cardiotoxicity Int J Cardiol 173 3 May 15 2014 519 521
9. Y.F. Hu, C.J. Liu, and P.M. Chang Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients Int J Cardiol 165 2 May 10 2013 355 357
10. A. Budaj-Fidecka, M. Kurzyna, and A. Fijałkowska In-hospital major bleeding predicts mortality in patients with pulmonary embolism: an analysis of ZATPOL registry data Int J Cardiol 168 4 Oct 9 2013 3543 3549
11. P. Pugliatti, R. Donato, G. Di Bella, S. Carerj, and S. Patanè Contrast-enhancing right atrial thrombus in cancer patient Int J Cardiol 173 3 May 15 2014 e35 e37
12. S. Grover, D.P. Leong, and A. Chakrabarty Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers Int J Cardiol 168 6 Oct 15 2013 5465 5467
13. W. Jurczak, S. Szmit, and M. Sobociński Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study Int J Cardiol 168 6 Oct 15 2013 5212 5217
14. C. Lestuzzi Cardioncology, oncocardiology. Are we barking up the wrong tree? Int J Cardiol 167 2 Jul 31 2013 307 309
15. P. Pugliatti, R. Donato, C. Zito, S. Carerj, and S. Patanè Cardio inhibitory vasovagal syncope in a cancer patient Int J Cardiol 174 2 Jun 15 2014 e64 e65
16. P. Pugliatti, C. De Gregorio, and S. Patanè The chance finding of echocardiographic complications of infective endocarditis Int J Cardiol 161 3 Nov 29 2012 e50 e51
17. S. Patanè Breast cancer treatment cardioprotective strategies: the King is naked; J Am Heart Assoc 2014 Published July 22,2014 http://www.jaha.ahajournals.org/content/3/2/e000665/reply
18. Y. Elkina, S. Palus, and A. Tschirner Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia Int J Cardiol 170 2 Dec 10 2013 160 166
19. J. Springer, A. Tschirner, K. Hartman, S. von Haehling, S.D. Anker, and W. Doehner The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy Int J Cardiol 168 4 Oct 9 2013 3527 3531
20. S. Palus, S. von Haehling, and V.C. Flach Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia Int J Cardiol 168 4 Oct 9 2013 3412 3418
21. V. Avbelj, and R. Trobec A closer look at electrocardiographic P waves before and during spontaneous cardioinhibitory syncope Int J Cardiol 166 3 Jul 1 2013 e59 e61
22. W.J. Jang, H.R. Yim, S.H. Lee, S.J. Park, J.S. Kim, and Y.K. On Prognosis after tilt training in patients with recurrent vasovagal syncope Int J Cardiol 168 4 Oct 9 2013 4264 4265
23. K.P. Loh, and O. Ogunneye Malignant cardioinhibitory vasovagal syncope - an uncommon cardiovascular complication of Roux-en-Y gastric bypass surgery: the fainting syndrome! Int J Cardiol 164 3 Apr 15 2013 e38 e39
24. S. Patanè, and F. Marte Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system Eur Heart J 30 10 May 2009 1169 1170
25. M. Arcopinto, C.A. Cella, and R. Wesolowski Primary prevention of cancer-related thrombosis: special focus on ambulatory patients Int J Cardiol 173 3 May 15 2014 583 584
26. S. Patanè Is there a role for quinazoline-based α(1)-adrenoceptor antagonists in cardio-oncology ? Card Drugs therapy 2014 accepted
27. D. Cardinale [A new frontier: cardio-oncology]. Cardiologia. 41 9 Sep 1996 887 891
28. S. Patanè, and F. Marte Prostate-specific antigen kallikrein and acute myocardial infarction: where we are. Where are we going? Int J Cardiol 146 1 Jan 7 2011 e20 e22
29. S. Patanè, and F. Marte Prostate-specific antigen and acute myocardial infarction: a possible new intriguing scenario Int J Cardiol 134 3 May 29 2009 e147 e149
30. S. Patanè Prostate-specific antigen kallikrein and the heart World J Cardiol 1 1 Dec 31 2009 23 25
31. G.M. Calvagna, and S. Patanè Transvenous pacemaker lead extraction in infective endocarditis Int J Cardiol 176 2 Jul 12 2014 511 513
32. S. Patanè Is there a need for bacterial endocarditis prophylaxis in patients undergoing urological procedures? J Cardiovasc Transl Res 7 3 Apr 2014 369 371
33. S. Patanè Is there a need for bacterial endocarditis prophylaxis in patients undergoing gastrointestinal endoscopy? J Cardiovasc Transl Res 7 3 Apr 2014 372 374
34. S. Patanè A dark side of the cardio-oncology: the bacterial endocarditis prophylaxis Int J Cardiol 157 3 Jun 14 2012 448 449
35. S. Patanè Cardiotoxicity: cisplatin and long term cancer survivors Int J Cardiol 175 1 Jul 15 2014 201 202
36. S. Patanè A challenge in cardiology: the oncosurgery Int J Cardiol 174 2 Jun 15 2014 411 412
37. S. Patanè Insights into cardio-oncology: adrenergic receptor signaling and pathways in breast cancer Curr Med Res Opin Jun 26 2014 1 2
38. S. Patanè, F. Marte, M. Sturiale, and G. Dattilo ST-segment elevation and diminution of prostate-specific antigen in a patient with coronary spasm and without significant coronary stenoses Int J Cardiol 148 2 Apr 14 2011 e31 e33
39. M. Scarano, F. Pezzuoli, G. Torrisi, G.M. Calvagna, and S. Patanè Cardiovascular implantable electronic device infective endocarditis Int J Cardiol 173 3 May 15 2014 e38 e39
40. K.L. Wang, C.J. Liu, and T.F. Chao Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis Int J Cardiol 167 5 Sep 1 2013 2162 2166
41. B. Ky, P. Vejpongsa, E.T. Yeh, T. Force, and J.J. Moslehi Emerging paradigms in cardiomyopathies associated with cancer therapies Circ Res 113 6 Aug 30 2013 754 764
42. S. Patanè Heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies J Card Fail 20 6 Jun 2014 456 457
43. S. Patanè HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs Int J Cardiol 176 3 Aug 2 2014 1082 1085
44. S. Patanè Cardiotoxicity: anthracyclines and long term cancer survivors Int J Cardiol 176 3 Aug 4 2014 1326 1328
45. D.J. Lenihan Cardiac biomarkers, cardiotoxicity, and active collaboration: is this the final frontier or the wave we should catch? J Am Coll Cardiol 63 8 Mar 4 2014 817 818
46. J. Sun, J. Zhang, and W. Yan Iloprost prevents doxorubicin mediated human cardiac progenitor cell depletion Int J Cardiol 176 2 Jul 12 2014 536 539
47. S.H. Lee, and Y.S. Kim Reversible dilated cardiomyopathy associated with long-term anagrelide therapy in a patient with chronic myeloproliferative disease: a serial 2-dimensional speckle tracking echocardiographic study Int J Cardiol 173 3 May 15 2014 e45 e46
48. G. Fried, T. Regev, and M. Moskovitz Trastuzumab-related cardiac events in the treatment of early breast cancer Breast Cancer Res Treat 142 1 Nov 2013 1 7
49. A. Sandoo, G.D. Kitas, and A.R. Carmichael Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer Anticancer Res 34 3 Mar 2014 1147 1151
50. S. Patanè Ebola: is there a hope from treatment with cardiovascular drugs? Int J Cardiol 2014 [accepted for publication]
51. S. Patanè ERBB1/ EGFR and ERBB2 (HER2/neu) - targeted therapies in cancer and cardiovascular system with cardiovascular drugs Int J Cardiol 176 3 Aug 2 2014 1082 1085
52. S. Patanè Cancer multidrug resistance - targeted therapy in both cancer and cardiovascular system with cardiovascular drugs Int J Cardiol 176 3 Aug 2 2014 1306 1308
53. S. Mokuyasu, Y. Suzuki, E. Kawahara, T. Seto, and Y. Tokuda High-sensitivity cardiac troponin I detection for 2 types of drug-induced cardiotoxicity in patients with breast cancer Breast Cancer Feb 23 2014 [Epub ahead of print]
54. M. Zeglinski, A. Ludke, D.S. Jassal, and P.K. Singal Trastuzumab-induced cardiac dysfunction: a 'dual-hit' Exp Clin Cardiol 16 3 Fall 2011 70 74
55. S. Di Cosimo Heart to heart with trastuzumab: a review on cardiac toxicity Target Oncol 6 4 Dec 2011 189 195
56. M. Ewer, and S. Lippman Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity J Clin Oncol 23 13 May 1 2005 2900 2902
57. C.G. Lenneman, W.M. Abdallah, and H.M. Smith Sympathetic nervous system alterations with HER2 + antagonism: an early marker of cardiac dysfunction with breast cancer treatment? Ecancer Med Sci 8 Jul 17 2014 446
58. A. Saidi, and R. Alharethi Management of chemotherapy induced cardiomyopathy Curr Cardiol Rev 7 4 Nov 2011 245 249
59. S.A. Francis, S. Cheng, C.L. Arteaga, and J. Moslehi Heart failure and breast cancer therapies: moving towards personalized risk assessment J Am Heart Assoc 3 1 Feb 28 2014 e000780
60. G. Ezaz, J.B. Long, C.P. Gross, and J. Chen Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer J Am Heart Assoc 3 1 Feb 28 2014 e000472
61. T. Marinko, J. Dolenc, and C. Bilban-Jakopin Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer Radiol Oncol 48 2 Apr 25 2014 105 112
62. O. Yavas, M. Yazici, O. Eren, and B. Oyan The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients Swiss Med Wkly 137 2007 556 558
63. C. Ferguson, J. Clarke, and N.A. Herity Ventricular tachycardia associated with trastuzumab N Engl J Med 354 2006 648 649
64. R.L. Olin, S.S. Desai, K. Fox, and R. Davidson Non-myopathic cardiac events in two patients treated with trastuzumab Breast J 13 2007 211 212
65. T.M. Suter, and M.S. Ewer Cancer drugs and the heart: importance and management Eur Heart J 34 15 Apr 2013 1102 1111
66. A. Dirican, F. Levent, and A. Alacacioglu Acute cardiotoxic effects of adjuvant trastuzumab treatment and its relation to oxidative stress Angiology Feb 26 2014 [Epub ahead of print]
67. O. Tanriverdi, N. Meydan, and S. Barutca Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer: a pilot study Med Oncol 29 5 Dec 2012 3265 3271
68. G. Russo, G. Cioffi, and S. Gori ICARO (Italian CARdio-Oncological) Network. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer J Cardiovasc Med (Hagerstown) 15 2 Feb 2014 141 146
69. M.H. Santos Detection of subclinical trastuzumab-induced cardiotoxicity in patients with breast cancer Arq Bras Cardiol 10 1 Jul 2013 2 3
70. G. Gulati, K.W. Zhang, M. Scherrer-Crosbie, and B. Ky Cancer and cardiovascular disease: the use of novel echocardiography measures to predict subsequent cardiotoxicity in breast cancer treated with anthracyclines and trastuzumab Curr Heart Fail Rep Jul 31 2014 [Epub ahead of print]
71. M.K. ElZarrad, P. Mukhopadhyay, and N. Mohan Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice PLoS ONE 8 11 Nov 8 2013 e79543
72. Erratum PLoS ONE 9(1) 2014 10.1371/annotation/3ba18ef8-8c9c-45ab-9bc5-ad571a54a28c
73. D.A. Yardley, D. Tripathy, and A.M. Brufsky Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER Br J Cancer 110 11 May 27 2014 2756 2764
74. J. Truong, A.T. Yan, G. Cramarossa, and K.K. Chan Chemotherapy-induced cardiotoxicity: detection, prevention, and management Can J Cardiol 30 8 Aug 2014 869 878
75. R.M. Steingart, N. Yadav, C. Manrique, J.R. Carver, and J. Liu Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management Semin Oncol 40 6 Dec 2013 690 708
76. R.J. Sheppard, J. Berger, and I.A. Sebag Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy Front Pharmacol 4 Mar 12 2013 19
77. K. Kalam, and T.H. Marwick Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis Eur J Cancer 49 13 Sep 2013 2900 2909
78. A. Thakur, and R.M. Witteles Cancer therapy-induced left ventricular dysfunction: interventions and prognosis J Card Fail 20 3 2014 March 155 158
79. A.A. Onitilo, J.M. Engel, R.V. Stankowski, H. Liang, R.L. Berg, and S.A. Doi High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study Breast Cancer Res Treat 134 1 Jul 2012 291 298
80. W.Y. Cheung, R. Levin, and S. Setoguchi Appropriateness of cardiovascular care in elderly adult cancer survivors Med Oncol 30 2 2013 561
81. M. Ammon, N. Arenja, and G. Leibundgut Cardiovascular management of cancer patients with chemotherapy-associated left ventricular systolic dysfunction in real-world clinical practice J Card Fail 9 9 2013 629 634
82. M.L. Canale, A. Camerini, M. Magnacca, and G. Casolo A cardio-oncology experience in Italy: results of a Tuscany regional-based survey J Cardiovasc Med (Hagerstown) 15 2 Feb 2014 135 140
83. L.M. Budden, B.A. Hayes, and P.G. Buettner Women's decision satisfaction and psychological distress following early breast cancer treatment: a treatment decision support role for nurses Int J Nurs Pract 20 1 Feb 2014 8 16
84. N. Obi, D. Gornyk, and J. Heinz Determinants of newly diagnosed comorbidities among breast cancer survivors J Cancer Surviv 8 3 Sep 2014 384 393
85. A.L. McCarthy, P. Yates, and R.Z. Shaban Cross-sectional survey of the health behaviour of southeast Queensland women with cancer-treatment induced menopause: implications for cancer and primary care nurses Collegian 20 4 2013 223 231
86. K.M. Mazor, D.W. Roblin, and S.M. Greene Toward patient-centered cancer care: patient perceptions of problematic events, impact, and response J Clin Oncol 30 15 May 20 2012 1784 1790
87. C.D. Prouty, K.M. Mazor, and S.M. Greene Providers' perceptions of communication breakdowns in cancer care J Gen Intern Med 29 8 Aug 2014 1122 1130
88. A. Abernethy, E. Abrahams, and A. Barker Turning the tide against cancer through sustained medical innovation: the pathway to progress Clin Cancer Res 20 5 1 Mar 2014 1081 1086
89. S. Nafi, D. Generali, and G. Kramer-Marek Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer Oncotarget Apr 17 2014 [Epub ahead of print]